Advertisement

A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration

      Abstract

      Plasma fibrinogen is strongly associated with cardiovascular morbi-mortality. We investigated in the large cohort of the D.E.S.I.R. (data from an epidemiological study on the insulin resistance syndrome) study, the relationship between change in fibrinogen concentration over a 3-year follow-up and fibrate and statin use. Fibrinogen concentrations were higher at baseline among individuals treated with statins (n=130) compared to those treated with fibrates (n=251), even after adjustment for confounding factors (including total cholesterol, HDL cholesterol and triglycerides) (mean (S.D.): 2.8 (0.6) vs. 3.1 (0.6), P<0.001). We compared change in fibrinogen concentrations at 3 years of follow-up, between individuals who started fibrate (n=126) or statin (n=127) treatment during the follow-up and individuals (n=3906) who stayed without treatment during this period. After adjustment for baseline fibrinogen level, age, sex and changes in total cholesterol, triglycerides and alcohol intake, fibrinogen concentration decreased after fibrate treatment, while it increased after statin treatment and in those not using lipid lowering drugs (−0.07 (0.54) vs. 0.10 (0.54) vs. 0.08 (0.52) g/l respectively, P=0.01). No differences were observed between different statins or different fibrates. In conclusion, fibrates in contrast with statins may combine lipid-lowering with a beneficial effect on fibrinogen. This effect is independent of changes in cholesterol and triglyceride concentrations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ernst E.
        • Koenig W.
        Fibrinogen and cardivoascular risk.
        Vasc. Med. 1997; 2: 115-125
        • Meade T.W.
        • Mellows S.
        • Brozovic M.
        • Miller G.J.
        • Chakrabarti R.R.
        • North W.R.
        • Haines A.P.
        • Stirling Y.
        • Imeson J.D.
        • Thompson S.G.
        Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.
        Lancet. 1986; 6: 533-537
        • Kannel W.B.
        • Wolf P.A.
        • Castelli W.P.
        • D'Agostino R.B.
        Fibrinogen and risk of cardiovascular disease: the Framingham Study.
        J. Am. Med. Assoc. 1987; 9: 1183-1186
        • La Rosa J.C.
        • He J.
        • Vupputuri S.
        Effect of statins on risk of coronary disease. A meta-analysis of randomised controlled trials.
        J. Am. Med. Assoc. 1999; 282: 2340-2346
        • Rosenson R.S.
        • Tangney C.C.
        Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction.
        J. Am. Med. Assoc. 1998; 279: 1643-1650
        • Durrington P.N.
        • Mackness M.I.
        • Bhatnagar D.
        • Julier K.
        • Prais H.
        • Arrol S.
        • Morgan J.
        • Wood G.N.I.
        Effects of two different fibric acid derivates on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
        Atherosclerosis. 1998; 138: 217-225
        • Branchi A.
        • Rovellini A.
        • Sommariva D.
        • Gugliandolo A.G.
        • Fasoli A.
        Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
        Thromb. Haemost. 1993; 70: 241-243
        • Tsuda Y.
        • Satoh K.
        • Kitadai M.
        • et al.
        Effects of pravastatin and simvastatin on plasma fibrinogen level and blood rheology in type II hyperliproteinemia.
        Atherosclerosis. 1996; 122: 225-233
        • Marais A.D.
        • Firth J.C.
        • Bateman M.E.
        • Byrnes P.
        • Martens C.
        • Mountney J.
        Atovarstatin: an effective lipid-modifying agent in familial hypercholesterolemia.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 1527-1531
        • Wierzbiki A.S.
        • Lumb P.J.
        • Semra Y.K.
        • Crook M.A.
        Effect of atovarstatin on plasma fibrinogen.
        Lancet. 1998; 351: 569-570
        • Mussoni L.
        • Mannucci L.
        • Sirtori C.
        • Pazzucconi F.
        • Bonfardeci G.
        • Cimminiello C.
        • Notarbartolo A.
        • Scafidi V.
        • Bittolo Bon G.
        • Alessandrini P.
        • Nenci G.
        • Parise P.
        • Colombo L.
        • Piliego T.
        • Tremoli E.
        Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
        Ahterosclerosis. 2000; 148: 397-406
        • de Maat M.P.M.
        • Knipscheer H.C.
        • Kastelein J.J.P.
        • Kluft C.
        Modulation of plasma fibrinogen levels by Ciprofibrate and Gemfibrozil in primary hyperlipidemia.
        Thromb. Haemost. 1997; 77: 75-79
        • Folsom A.R.
        • Wu K.K.
        • Davis C.E.
        • Conlan M.G.
        • Sorlie P.D.
        • Szklo M.
        Population correlates of plasma fibrinogen and factor VII, putative risk factors.
        Atherosclerosis. 1991; 91: 191-205
        • Pajak A.
        • Broda G.
        • Manolio T.A.
        • Kawalec E.
        • Rywik S.
        • Davis C.E.
        • Pikon J.
        • Pytlak A.
        Thomas RP. Constitutional, biochemical and lifestyle correlates of fibrinogen and factor VII activity in Polish urban and rural populations.
        Int. J. Epidemiol. 1998; 27: 953-961
        • Folsom A.R.
        • Wu K.K.
        • Rasmussen M.
        • Chambless L.E.
        • Aleksic N.
        • Nieto F.J.
        Determinants of population changes in fibrinogen and factor VII over 6 years. The Atherosclerosis Risk in Communities (ARIC) Study.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 601-606
        • Balleisen L.
        • Assmann G.
        • Bailey J.
        • Epping P.H.
        • Schulte H.
        • van de Loo J.
        Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population — II. Baseline data on the relation to blood pressure, blood glucose, uric acid and lipid fractions.
        Thromb. Haemost. 1985; 54: 721-723
        • The D.E.S.I.R. Study Group
        An epidemiological survey from a network of French Health Examination Centres: D.E.S.I.R. (Epidemiological Data on the Insulin Resistance Syndrome).
        Rev. Epidemiol. Sante Publique. 1996; 44: 373-375
        • SAS Institute Inc.
        SAS User's Guide, Basics, Version 6.12. SAS Institute, Inc, Cary, NC1996
        • Niort G.
        • Bulgarelli A.
        • Cassader M.
        • Pagano G.
        Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.
        Atherosclerosis. 1988; 71: 113-119
        • Maison P.
        • Guillemot D.
        • Sermet C.
        • Eschwège E.
        Change in lipid-lowering drug use in France according to cardiovascular risk level: before and after statin introduction.
        Fundam. Clin. Pharmacol. 1999; 13: 379
        • Bo M.
        • Bonino F.
        • Neirotti M.
        • Gottero M.
        • Pernigotti L.
        • Molaschi M.
        • Fabris F.
        Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs.
        Angiology. 1991; 42: 106-111
        • Mitropoulos K.A.
        • Armitage J.M.
        • Collins R.
        • Meade T.W.
        • Reeves B.E.
        • Wallendszus K.R.
        • Wilson S.S.
        • Lawson A.
        • Peto R.
        Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids.
        Eur. Heart J. 1997; 18: 235-241
        • Mayer J.
        • Eller T.
        • Brauer P.
        • Solleder E.M.
        • Schafer R.M.
        • Keller F.
        • Kochsiek K.
        Effects of long-term treatment with lovastatin on the clotting system and blood platelets.
        Ann. Hematol. 1992; 64: 196-201
        • Beigel Y.
        • Fuchs J.
        • Snir M.
        • Green P.
        • Lurie Y.
        • Djaldetti M.
        Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology.
        J. Clin. Pharmacol. 1991; 31: 512-517
        • Wada H.
        • Mori Y.
        • Kaneko T.
        • Wakita Y.
        • Minamikawa K.
        • Ohiwa M.
        • Tamaki S.
        • Yokoyama N.
        • Kobayashi T.
        • Deguchi K.
        Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin.
        Clin. Ther. 1992; 14: 829-834
        • Green F.
        • Humphries S.
        Control of plasma fibrinogen levels.
        Baillières Clin. Haematol. 1989; 2: 945-949
        • Di Minno G.
        • Mancini M.
        Drugs affecting plasma fibrinogen levels.
        Cardiovasc. Drugs Ther. 1992; 6: 25-27
        • Kockx M.
        • Princen H.M.G.
        • Kooistra T.
        Fibrate-modulated expression of fibrinogen, plasminogen avtivator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes.
        Thromb. Haemost. 1998; 80: 942-948
        • Kockx M.
        • de Maat M.P.M.
        • Knipscheer H.C.
        • Kastelein J.J.P.
        • Kluft C.
        • Princen H.M.G.
        • Kooistra T.
        Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidemic patients.
        Thromb. Haemost. 1997; 78: 1167-1172
        • Miller G.J.
        Lipoproteins and thrombosis: effects of lipid lowering.
        Curr. Opin. Lipidol. 1995; 6: 38-42
        • Mennen L.I.
        • Balkau B.
        • Charles M.A.
        • D'Hour A.
        • le Mauff J.M.
        Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking.
        Thromb. Haemost. 1999; 82: 1106-1111
        • Thompson S.G.
        • Kieanst M.A.
        • Pyke S.D.M.
        • Haverkate F.
        • van de Loo J.C.W.
        Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.
        New Engl. J. Med. 1995; 332: 635-641
        • Yarnell J.W.
        • Baker I.A.
        • Sweetnam P.M.
        • Bainton D.
        • O'Brien J.R.
        • Whitehead P.J.
        • Elwood P.C.
        Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Carphilly and Speedwell Collaborative Heart Disease studies.
        Circulation. 1991; 83: 836-844
        • Wilhelmsen L.
        • Svärdsudd K.
        • Korsan-Bengsten K.
        • Larsson B.
        • Welin L.
        • Tibblin G.
        Fibrinogen as a risk factor for stroke and myocardial infarction.
        New Engl. J. Med. 1984; 311: 501-505
        • Stone M.C.
        • Thorp J.M.
        Plasma fibrinogen: a major coronary risk factor.
        J. R. Coll. Gen. Pract. 1985; 35: 565-569
        • Pearson T.A.
        • La Cava J.
        • Weil H.F.C.
        Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease.
        Am. J. Clin. Nutr. 1997; 65: S1674-S1682
        • Scarabin P.Y.
        • Bara L.
        • Ricard S.
        • Poirier O.
        • Cambou J.P.
        • Arveiler D.
        • Luc G.
        • Evans A.E.
        • Samama M.M.
        • Cambien F.
        Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction.
        Arterioscler. Thromb. 1993; 13: 886-891
        • van der Bom J.G.
        • de Maat M.L.
        • Haverkate F.
        • Hofman A.
        • Kluft C.
        • Grobbee D.E.
        Elevated plasma fibrinogen: cause or consequence of cardiovascular disease?.
        Arteriocscler. Thromb. Vasc. Biol. 1998; 18: 621-625
        • The BIP Study Group
        Secondary Prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
        Circulation. 2000; 102: 21-27
        • Knopp R.H.
        Drug treatment of lipid disorders.
        New Eng. J. Med. 1999; 341: 498-511